Pharma Mar SA - Strategy, SWOT and Corporate Finance Report

Pharma Mar SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar’s developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Scope

  • Detailed information on Pharma Mar SA required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Pharma Mar SA in the form of a SWOT analysis
  • An in-depth view of the business model of Pharma Mar SA including a breakdown and examination of key business segments
  • News about Pharma Mar SA, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Pharma Mar SA and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Pharma Mar SA as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Pharma Mar SAs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Traslational Cancer Drugs Pharma SL

Oryzon Genomics SA

GP Pharm SA

CTI BioPharma Corp

Ariad Pharmaceuticals (Spain) SL

Ability Pharmaceuticals SL

Traslational Cancer Drugs Pharma SL

Oryzon Genomics SA

GP Pharm SA

CTI BioPharma Corp

Ariad Pharmaceuticals (Spain) SL

Ability Pharmaceuticals SL

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Pharma Mar SA ...

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Pharma Mar SA - Key Facts 6

Pharma Mar SA - Key Employees 7

Pharma Mar SA - Key Employee Biographies 8

Pharma Mar SA - Major Products and Services 9

Pharma Mar SA - History 10

Pharma Mar SA - Company Statement 12

Pharma Mar SA - Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2 – Company Analysis 16

Company Overview 16

Pharma Mar SA - Business Description 16

Business Segment: Biopharmaceuticals 16

Overview 16

Performance 16

Business Segment: Consumer Chemicals 17

Overview 17

Performance 17

Geographical Segment: Germany 17

Performance 17

Geographical Segment: Italy 17

Performance 17

Geographical Segment: Japan 17

Performance 17

Geographical Segment: Rest of the European Union 17

Performance 17

Geographical Segment: Rest of the World 17

Performance 17

Geographical Segment: Spain 18

Performance 18

Geographical Segment: the US 18

Performance 18

R&D Overview 18

Pharma Mar SA - Corporate Strategy 19

Pharma Mar SA - SWOT Analysis 20

SWOT Analysis - Overview 20

Pharma Mar SA - Strengths 20

Pharma Mar SA - Weaknesses 21

Pharma Mar SA - Opportunities 22

Pharma Mar SA - Threats 23

Pharma Mar SA - Key Competitors 24

Section 3 – Company Financial Ratios 25

Financial Ratios - Capital Market Ratios 25

Financial Ratios - Annual Ratios 26

Performance Chart 29

Financial Performance 29

Financial Ratios - Interim Ratios 30

Financial Ratios - Ratio Charts 31

Section 4 – Company’s Lifesciences Financial Deals and Alliances 32

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33

Pharma Mar SA, Recent Deals Summary 34

Section 5 – Company’s Recent Developments 35

Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results 35

Feb 28, 2018: PharmaMar group announces 2017 earnings results 36

Oct 24, 2017: Pharma Mar group revenues totalled €140 million in the first nine months of the year 37

Jul 26, 2017: Pharma Mar group reports first half financial results 38

Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 39

Apr 27, 2017: PharmaMar Demonstrates Its Progress in R&D in New York 40

Apr 27, 2017: PharmaMar Group reports €45.5 million in revenues (+8%) 41

Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 42

Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 44

Section 6 – Appendix 46

Methodology 46

Ratio Definitions 46

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Tables

List of Tables

Pharma Mar SA, Key Facts 6

Pharma Mar SA, Key Employees 7

Pharma Mar SA, Key Employee Biographies 8

Pharma Mar SA, ...

List of Tables

Pharma Mar SA, Key Facts 6

Pharma Mar SA, Key Employees 7

Pharma Mar SA, Key Employee Biographies 8

Pharma Mar SA, Major Products and Services 9

Pharma Mar SA, History 10

Pharma Mar SA, Subsidiaries 14

Pharma Mar SA, Key Competitors 24

Pharma Mar SA, Ratios based on current share price 25

Pharma Mar SA, Annual Ratios 26

Pharma Mar SA, Annual Ratios (Cont...1) 27

Pharma Mar SA, Annual Ratios (Cont...2) 28

Pharma Mar SA, Interim Ratios 30

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33

Pharma Mar SA, Recent Deals Summary 34

Currency Codes 46

Capital Market Ratios 46

Equity Ratios 47

Profitability Ratios 47

Cost Ratios 48

Liquidity Ratios 48

Leverage Ratios 49

Efficiency Ratios 49

List of Figures

List of Figures

Pharma Mar SA, Performance Chart (2013 - 2017) 29

Pharma Mar SA, Ratio Charts 31

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals ...

List of Figures

Pharma Mar SA, Performance Chart (2013 - 2017) 29

Pharma Mar SA, Ratio Charts 31

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 33

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports